Green Cross Lab Cell Corporation Market Cap ($102.86 Million)
Market Cap & Net Worth: Green Cross Lab Cell Corporation (144510)
Green Cross Lab Cell Corporation market cap. Green Cross Lab Cell Corporation (KQ:144510) has a market capitalization of $102.86 Million (₩151.77 Billion) as of November 1, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #18898 globally and #895 in its home market, demonstrating a -24.96% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Green Cross Lab Cell Corporation's stock price ₩10100.00 by its total outstanding shares 15027141 (15.03 Million). Also see cash flow conversion of Green Cross Lab Cell Corporation for how efficiently the company converts equity into cash flow.
Green Cross Lab Cell Corporation Market Cap History (2016–2026)
Green Cross Lab Cell Corporation market cap history from 2016 to 2026. Data shows change from $249.11 Million to $102.86 Million (-13.79% CAGR). Check Green Cross Lab Cell Corporation stock quote for real-time trading data and today's change.
Index Memberships
Green Cross Lab Cell Corporation is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$208.91 Billion | 0.05% | #346 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$208.91 Billion | 0.05% | #346 of 1384 |
Weight: Green Cross Lab Cell Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Green Cross Lab Cell Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Green Cross Lab Cell Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Green Cross Lab Cell Corporation equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Green Cross Lab Cell Corporation's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $249.11 Million | $42.42 Billion | $2.33 Billion | 0.01x | 0.11x |
| 2017 | $499.77 Million | $45.80 Billion | $1.06 Billion | 0.01x | 0.47x |
| 2018 | $459.15 Million | $50.62 Billion | $1.00 Billion | 0.01x | 0.46x |
| 2019 | $379.39 Million | $57.90 Billion | -$2.28 Billion | 0.01x | N/A |
| 2020 | $923.05 Million | $85.56 Billion | $4.16 Billion | 0.01x | 0.22x |
| 2021 | $1.02 Billion | $168.31 Billion | $31.42 Billion | 0.01x | 0.03x |
| 2022 | $476.34 Million | $236.12 Billion | $24.37 Billion | 0.00x | 0.02x |
| 2023 | $463.36 Million | $187.54 Billion | -$174.01 Million | 0.00x | N/A |
| 2024 | $241.35 Million | $174.45 Billion | -$73.90 Billion | 0.00x | N/A |
| 2025 | $253.06 Million | $165.52 Billion | -$272.86 Billion | 0.00x | N/A |
Competitor Companies of 144510 by Market Capitalization
Companies near Green Cross Lab Cell Corporation in the global market cap rankings as of November 1, 2026. Also see Green Cross Lab Cell Corporation assets under control for a full breakdown of the balance sheet.
Key companies related to Green Cross Lab Cell Corporation by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $164.04 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #480 globally with a market cap of $56.33 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #530 globally with a market cap of $51.40 Billion USD ( CN¥351.23 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $697.00 |
| #143 | Danaher Corporation | NYSE:DHR | $164.04 Billion | $232.23 |
| #480 | Natera Inc | NASDAQ:NTRA | $56.33 Billion | $414.30 |
| #530 | WuXi AppTec Co Ltd | SHG:603259 | $51.40 Billion | CN¥142.01 |
Market Capitalization of Green Cross Lab Cell Corporation (2016–2026)
Market capitalization of Green Cross Lab Cell Corporation from 2016 to today. Between 2016 and today, Green Cross Lab Cell Corporation's market cap moved from $249.11 Million to $ 102.86 Million, with a yearly change of -13.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩102.86 Million | -59.36% |
| 2025 | ₩253.06 Million | +4.85% |
| 2024 | ₩241.35 Million | -47.91% |
| 2023 | ₩463.36 Million | -2.73% |
| 2022 | ₩476.34 Million | -53.31% |
| 2021 | ₩1.02 Billion | +10.54% |
| 2020 | ₩923.05 Million | +143.30% |
| 2019 | ₩379.39 Million | -17.37% |
| 2018 | ₩459.15 Million | -8.13% |
| 2017 | ₩499.77 Million | +100.62% |
| 2016 | ₩249.11 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Green Cross Lab Cell Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $102.86 Million USD |
| MoneyControl | $102.86 Million USD |
| MarketWatch | $102.86 Million USD |
| marketcap.company | $102.86 Million USD |
| Reuters | $102.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Green Cross Lab Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in Nove… Read more